{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T15:37:37Z","timestamp":1792424257509,"version":"4.5.0"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-024-55665-1","type":"journal-article","created":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T22:45:26Z","timestamp":1738363526000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Proteomic profiling identifies muscle-invasive bladder cancers with distinct biology and responses to platinum-based chemotherapy"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-9315-6238","authenticated-orcid":false,"given":"A.","family":"Contreras-Sanz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7722-8888","authenticated-orcid":false,"given":"G. L.","family":"Negri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. J.","family":"Reike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8514-2713","authenticated-orcid":false,"given":"H. Z.","family":"Oo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. M.","family":"Scurll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6446-1584","authenticated-orcid":false,"given":"S. E.","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0225-4173","authenticated-orcid":false,"given":"G.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6784-5978","authenticated-orcid":false,"given":"C. L.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8775-503X","authenticated-orcid":false,"given":"S.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5850-7985","authenticated-orcid":false,"given":"M. E.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5985-3698","authenticated-orcid":false,"given":"D. M.","family":"Berman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Seiler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8949-4374","authenticated-orcid":false,"given":"G. B.","family":"Morin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2919-7068","authenticated-orcid":false,"given":"P. C.","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,1]]},"reference":[{"key":"55665_CR1","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay, J. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136, E359\u2013E386 (2015).","journal-title":"Int. J. Cancer"},{"key":"55665_CR2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"55665_CR3","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1016\/S0140-6736(16)30512-8","volume":"388","author":"AM Kamat","year":"2016","unstructured":"Kamat, A. M. et al. Bladder cancer. Lancet 388, 2796\u20132810 (2016).","journal-title":"Lancet"},{"key":"55665_CR4","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","volume":"349","author":"HB Grossman","year":"2003","unstructured":"Grossman, H. B. et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N. Engl. J. Med. 349, 859\u2013866 (2003).","journal-title":"N. Engl. J. Med."},{"key":"55665_CR5","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.eururo.2017.05.016","volume":"72","author":"B Bhindi","year":"2017","unstructured":"Bhindi, B. et al. Oncologic outcomes for patients with residual cancer at cystectomy following neoadjuvant chemotherapy: a pathologic stage-matched analysis. Eur. Urol. 72, 660\u2013664 (2017).","journal-title":"Eur. Urol."},{"key":"55665_CR6","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","volume":"171","author":"AG Robertson","year":"2017","unstructured":"Robertson, A. G. et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell 171, 540\u2013556 e525 (2017).","journal-title":"Cell"},{"key":"55665_CR7","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/path.4886","volume":"242","author":"G Sjodahl","year":"2017","unstructured":"Sjodahl, G., Eriksson, P., Liedberg, F. & Hoglund, M. Molecular classification of urothelial carcinoma: global mRNA classification versus tumour-cell phenotype classification. J. Pathol. 242, 113\u2013125 (2017).","journal-title":"J. Pathol."},{"key":"55665_CR8","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.eururo.2017.03.030","volume":"72","author":"R Seiler","year":"2017","unstructured":"Seiler, R. et al. Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy. Eur. Urol. 72, 544\u2013554 (2017).","journal-title":"Eur. Urol."},{"key":"55665_CR9","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","volume":"77","author":"A Kamoun","year":"2020","unstructured":"Kamoun, A. et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur. Urol. 77, 420\u2013433 (2020).","journal-title":"Eur. Urol."},{"key":"55665_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.10.035","author":"G Sj\u00f6dahl","year":"2021","unstructured":"Sj\u00f6dahl, G. et al. Different responses to neoadjuvant chemotherapy in urothelial carcinoma molecular subtypes. Eur. Urol. https:\/\/doi.org\/10.1016\/j.eururo.2021.10.035 (2021).","journal-title":"Eur. Urol."},{"key":"55665_CR11","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-18640-0","volume":"11","author":"A Taber","year":"2020","unstructured":"Taber, A. et al. Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis. Nat. Commun. 11, 4858 (2020).","journal-title":"Nat. Commun."},{"key":"55665_CR12","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","volume":"25","author":"W Choi","year":"2014","unstructured":"Choi, W. et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 25, 152\u2013165 (2014).","journal-title":"Cancer Cell"},{"key":"55665_CR13","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.eururo.2020.02.028","volume":"77","author":"A Necchi","year":"2020","unstructured":"Necchi, A. et al. Impact of molecular subtyping and immune infiltration on pathological response and outcome following neoadjuvant pembrolizumab in muscle-invasive bladder cancer. Eur. Urol. 77, 701\u2013710 (2020).","journal-title":"Eur. Urol."},{"key":"55665_CR14","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1038\/s41591-019-0628-7","volume":"25","author":"T Powles","year":"2019","unstructured":"Powles, T. et al. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nat. Med. 25, 1706\u20131714 (2019).","journal-title":"Nat. Med."},{"key":"55665_CR15","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.eururo.2015.08.034","volume":"69","author":"DJ McConkey","year":"2016","unstructured":"McConkey, D. J. et al. A prognostic gene expression signature in the molecular classification of chemotherapy-naive urothelial cancer is predictive of clinical outcomes from neoadjuvant chemotherapy: a phase 2 trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with bevacizumab in urothelial cancer. Eur. Urol. 69, 855\u2013862 (2016).","journal-title":"Eur. Urol."},{"key":"55665_CR16","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/JU.0000000000002261","volume":"207","author":"Y Lotan","year":"2022","unstructured":"Lotan, Y. et al. Patients with muscle-invasive bladder cancer with nonluminal subtype derive greatest benefit from platinum based neoadjuvant chemotherapy. J. Urol. 207, 541\u2013550 (2022).","journal-title":"J. Urol."},{"key":"55665_CR17","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1158\/1078-0432.CCR-16-2520","volume":"23","author":"MY Teo","year":"2017","unstructured":"Teo, M. Y. et al. DNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma. Clin. Cancer Res. 23, 3610\u20133618 (2017).","journal-title":"Clin. Cancer Res."},{"key":"55665_CR18","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1158\/2159-8290.CD-14-0623","volume":"4","author":"EM Van Allen","year":"2014","unstructured":"Van Allen, E. M. et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov. 4, 1140\u20131153 (2014).","journal-title":"Cancer Discov."},{"key":"55665_CR19","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1001\/jamaoncol.2016.1056","volume":"2","author":"D Liu","year":"2016","unstructured":"Liu, D. et al. Clinical validation of chemotherapy response biomarker ERCC2 in muscle-invasive urothelial bladder carcinoma. JAMA Oncol. 2, 1094\u20131096, (2016).","journal-title":"JAMA Oncol."},{"key":"55665_CR20","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1158\/1078-0432.CCR-18-1001","volume":"25","author":"Q Li","year":"2019","unstructured":"Li, Q. et al. ERCC2 helicase domain mutations confer nucleotide excision repair deficiency and drive cisplatin sensitivity in muscle-invasive bladder cancer. Clin. Cancer Res. 25, 977\u2013988 (2019).","journal-title":"Clin. Cancer Res."},{"key":"55665_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2022.07.023","author":"A Gil-Jimenez","year":"2022","unstructured":"Gil-Jimenez, A. et al. Assessment of predictive genomic biomarkers for response to cisplatin-based neoadjuvant chemotherapy in bladder cancer. Eur. Urol. https:\/\/doi.org\/10.1016\/j.eururo.2022.07.023 (2022).","journal-title":"Eur. Urol."},{"key":"55665_CR22","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.eururo.2015.07.009","volume":"68","author":"ER Plimack","year":"2015","unstructured":"Plimack, E. R. et al. Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer. Eur. Urol. 68, 959\u2013967 (2015).","journal-title":"Eur. Urol."},{"key":"55665_CR23","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.euo.2020.02.003","volume":"3","author":"B Miron","year":"2020","unstructured":"Miron, B. et al. Defects in DNA repair genes confer improved long-term survival after cisplatin-based neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur. Urol. Oncol. 3, 544\u2013547 (2020).","journal-title":"Eur. Urol. Oncol."},{"key":"55665_CR24","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1200\/JCO.2023.41.6_suppl.438","volume":"41","author":"DM Geynisman","year":"2023","unstructured":"Geynisman, D. M. et al. A phase II trial of risk-enabled therapy after initiating neoadjuvant chemotherapy for bladder cancer (RETAIN). J. Clin. Oncol. 41, 438\u2013438 (2023).","journal-title":"J. Clin. Oncol."},{"key":"55665_CR25","doi-asserted-by":"crossref","DOI":"10.1002\/2056-4538.12363","volume":"10","author":"J Griffin","year":"2024","unstructured":"Griffin, J. et al. Verification of molecular subtyping of bladder cancer in the GUSTO clinical trial. J. Pathol. Clin. Res. 10, e12363 (2024).","journal-title":"J. Pathol. Clin. Res."},{"key":"55665_CR26","doi-asserted-by":"crossref","DOI":"10.1002\/prca.201800113","volume":"13","author":"S Doll","year":"2019","unstructured":"Doll, S., Gnad, F. & Mann, M. The Case for proteomics and phospho-proteomics in personalized cancer medicine. Proteom. Clin. Appl. 13, e1800113 (2019).","journal-title":"Proteom. Clin. Appl."},{"key":"55665_CR27","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nature18003","volume":"534","author":"P Mertins","year":"2016","unstructured":"Mertins, P. et al. Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55\u201362 (2016).","journal-title":"Nature"},{"key":"55665_CR28","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-28524-0","volume":"13","author":"K Asleh","year":"2022","unstructured":"Asleh, K. et al. Proteomic analysis of archival breast cancer clinical specimens identifies biological subtypes with distinct survival outcomes. Nat. Commun. 13, 896 (2022).","journal-title":"Nat. Commun."},{"key":"55665_CR29","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ccell.2021.12.006","volume":"40","author":"L Dong","year":"2022","unstructured":"Dong, L. et al. Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma. Cancer Cell 40, 70\u201387 e15 (2022).","journal-title":"Cancer Cell"},{"key":"55665_CR30","volume":"14","author":"Z Yao","year":"2023","unstructured":"Yao, Z. et al. Proteogenomics of different urothelial bladder cancer stages reveals distinct molecular features for papillary cancer and carcinoma in situ. Nat. Commun. 14, 5670 (2023).","journal-title":"Nat. Commun."},{"key":"55665_CR31","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13045-022-01291-7","volume":"15","author":"N Xu","year":"2022","unstructured":"Xu, N. et al. Integrated proteogenomic characterization of urothelial carcinoma of the bladder. J. Hematol. Oncol. 15, 76 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"55665_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.05.037","author":"CS Groeneveld","year":"2023","unstructured":"Groeneveld, C. S. et al. Proteogenomic characterization of bladder cancer reveals sensitivity to apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand in FGFR3-mutated tumors. Eur. Urol. https:\/\/doi.org\/10.1016\/j.eururo.2023.05.037 (2023).","journal-title":"Eur. Urol."},{"key":"55665_CR33","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41596-018-0082-x","volume":"14","author":"CS Hughes","year":"2019","unstructured":"Hughes, C. S. et al. Single-pot, solid-phase-enhanced sample preparation for proteomics experiments. Nat. Protoc. 14, 68\u201385 (2019).","journal-title":"Nat. Protoc."},{"key":"55665_CR34","volume":"6","author":"CS Hughes","year":"2016","unstructured":"Hughes, C. S. et al. Quantitative profiling of single formalin fixed tumour sections: proteomics for translational research. Sci. Rep. 6, 34949 (2016).","journal-title":"Sci. Rep."},{"key":"55665_CR35","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1158\/1078-0432.CCR-18-3558","volume":"25","author":"J Batista da Costa","year":"2019","unstructured":"Batista da Costa, J. et al. Molecular characterization of neuroendocrine-like bladder cancer. Clin. Cancer Res. 25, 3908\u20133920 (2019).","journal-title":"Clin. Cancer Res."},{"key":"55665_CR36","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nrurol.2014.129","volume":"11","author":"W Choi","year":"2014","unstructured":"Choi, W. et al. Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer. Nat. Rev. Urol. 11, 400\u2013410 (2014).","journal-title":"Nat. Rev. Urol."},{"key":"55665_CR37","volume":"14","author":"AG Robertson","year":"2023","unstructured":"Robertson, A. G. et al. Expression-based subtypes define pathologic response to neoadjuvant immune-checkpoint inhibitors in muscle-invasive bladder cancer. Nat. Commun. 14, 2126 (2023).","journal-title":"Nat. Commun."},{"key":"55665_CR38","volume":"2","author":"CD Hurst","year":"2021","unstructured":"Hurst, C. D. et al. Stage-stratified molecular profiling of non-muscle-invasive bladder cancer enhances biological, clinical, and therapeutic insight. Cell Rep. Med. 2, 100472 (2021).","journal-title":"Cell Rep. Med."},{"key":"55665_CR39","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-22465-w","volume":"12","author":"SV Lindskrog","year":"2021","unstructured":"Lindskrog, S. V. et al. An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer. Nat. Commun. 12, 2301 (2021).","journal-title":"Nat. Commun."},{"key":"55665_CR40","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32556","author":"R Stroggilos","year":"2019","unstructured":"Stroggilos, R. et al. Proteome-based classification of non-muscle invasive bladder cancer. Int. J. Cancer https:\/\/doi.org\/10.1002\/ijc.32556 (2019).","journal-title":"Int. J. Cancer"},{"key":"55665_CR41","volume":"11","author":"F Yu","year":"2020","unstructured":"Yu, F. et al. Identification of modified peptides using localization-aware open search. Nat. Commun. 11, 4065 (2020).","journal-title":"Nat. Commun."},{"key":"55665_CR42","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/s41592-020-0912-y","volume":"17","author":"F da Veiga Leprevost","year":"2020","unstructured":"da Veiga Leprevost, F. et al. Philosopher: a versatile toolkit for shotgun proteomics data analysis. Nat. Methods 17, 869\u2013870 (2020).","journal-title":"Nat. Methods"},{"key":"55665_CR43","doi-asserted-by":"crossref","first-page":"D1068","DOI":"10.1093\/nar\/gkx1143","volume":"46","author":"KC Cotto","year":"2018","unstructured":"Cotto, K. C. et al. DGIdb 3.0: a redesign and expansion of the drug-gene interaction database. Nucleic Acids Res. 46, D1068\u2013D1073 (2018).","journal-title":"Nucleic Acids Res."},{"key":"55665_CR44","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4548","author":"E Adib","year":"2021","unstructured":"Adib, E. et al. Phase II clinical trial of everolimus in a pan-cancer cohort of patients with mTOR pathway alterations. Clin. Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-4548 (2021).","journal-title":"Clin. Cancer Res."},{"key":"55665_CR45","doi-asserted-by":"publisher","unstructured":"Rimar, K. J., Tran, P. T., Matulewicz, R. S., Hussain, M. & Meeks, J. J. The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies. Cancer, https:\/\/doi.org\/10.1002\/cncr.30631 (2017).","DOI":"10.1002\/cncr.30631"},{"key":"55665_CR46","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1158\/1078-0432.CCR-22-1764","volume":"29","author":"N Klumper","year":"2023","unstructured":"Klumper, N. et al. Membranous NECTIN-4 expression frequently decreases during metastatic spread of urothelial carcinoma and is associated with enfortumab vedotin resistance. Clin. Cancer Res. 29, 1496\u20131505 (2023).","journal-title":"Clin. Cancer Res."},{"key":"55665_CR47","doi-asserted-by":"crossref","first-page":"39027","DOI":"10.1074\/jbc.M006700200","volume":"275","author":"N Verzijl","year":"2000","unstructured":"Verzijl, N. et al. Effect of collagen turnover on the accumulation of advanced glycation end products. J. Biol. Chem. 275, 39027\u201339031 (2000).","journal-title":"J. Biol. Chem."},{"key":"55665_CR48","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.cell.2019.12.023","volume":"180","author":"DP Nusinow","year":"2020","unstructured":"Nusinow, D. P. et al. Quantitative proteomics of the cancer cell line encyclopedia. Cell 180, 387\u2013402 e316 (2020).","journal-title":"Cell"},{"key":"55665_CR49","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms3612","volume":"4","author":"K Yoshihara","year":"2013","unstructured":"Yoshihara, K. et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat. Commun. 4, 2612 (2013).","journal-title":"Nat. Commun."},{"key":"55665_CR50","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","volume":"37","author":"AM Newman","year":"2019","unstructured":"Newman, A. M. et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat. Biotechnol. 37, 773\u2013782 (2019).","journal-title":"Nat. Biotechnol."},{"key":"55665_CR51","doi-asserted-by":"crossref","first-page":"D1519","DOI":"10.1093\/nar\/gkac1009","volume":"51","author":"X Shao","year":"2023","unstructured":"Shao, X. et al. MatrisomeDB 2.0: 2023 updates to the ECM-protein knowledge database. Nucleic Acids Res. 51, D1519\u2013D1530 (2023).","journal-title":"Nucleic Acids Res."},{"key":"55665_CR52","volume":"8","author":"D Liu","year":"2017","unstructured":"Liu, D. et al. Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer. Nat. Commun. 8, 2193 (2017).","journal-title":"Nat. Commun."},{"key":"55665_CR53","volume":"10","author":"M Gry","year":"2009","unstructured":"Gry, M. et al. Correlations between RNA and protein expression profiles in 23 human cell lines. BMC Genom. 10, 365 (2009).","journal-title":"BMC Genom."},{"key":"55665_CR54","doi-asserted-by":"publisher","unstructured":"Tan, T. Z., Rouanne, M., Tan, K. T., Huang, R. Y. & Thiery, J. P. Molecular subtypes of urothelial bladder cancer: results from a meta-cohort analysis of 2411 tumors. Eur. Urol. https:\/\/doi.org\/10.1016\/j.eururo.2018.08.027 (2018).","DOI":"10.1016\/j.eururo.2018.08.027"},{"key":"55665_CR55","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32737","author":"G Sjodahl","year":"2019","unstructured":"Sjodahl, G. et al. Molecular changes during progression from non-muscle invasive to advanced urothelial carcinoma. Int. J. Cancer https:\/\/doi.org\/10.1002\/ijc.32737 (2019).","journal-title":"Int. J. Cancer"},{"key":"55665_CR56","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-18794-x","volume":"11","author":"J Winkler","year":"2020","unstructured":"Winkler, J., Abisoye-Ogunniyan, A., Metcalf, K. J. & Werb, Z. Concepts of extracellular matrix remodelling in tumour progression and metastasis. Nat. Commun. 11, 5120 (2020).","journal-title":"Nat. Commun."},{"key":"55665_CR57","doi-asserted-by":"crossref","first-page":"5082","DOI":"10.1158\/1078-0432.CCR-18-1106","volume":"25","author":"R Seiler","year":"2019","unstructured":"Seiler, R. et al. Divergent biological response to neoadjuvant chemotherapy in muscle-invasive bladder cancer. Clin. Cancer Res. 25, 5082\u20135093 (2019).","journal-title":"Clin. Cancer Res."},{"key":"55665_CR58","doi-asserted-by":"publisher","unstructured":"Huan, J., Grivas, P., Birch, J. & Hansel, D. E. Emerging roles for mammalian target of rapamycin (mTOR) complexes in bladder cancer progression and therapy. Cancers 14, https:\/\/doi.org\/10.3390\/cancers14061555 (2022).","DOI":"10.3390\/cancers14061555"},{"key":"55665_CR59","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-022-09376-9","volume":"22","author":"S Bhattacharjee","year":"2022","unstructured":"Bhattacharjee, S. et al. PARP inhibitors chemopotentiate and synergize with cisplatin to inhibit bladder cancer cell survival and tumor growth. BMC Cancer 22, 312 (2022).","journal-title":"BMC Cancer"},{"key":"55665_CR60","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/cjp2.245","volume":"8","author":"CL Jackson","year":"2022","unstructured":"Jackson, C. L. et al. Diagnostic and prognostic implications of a three-antibody molecular subtyping algorithm for non-muscle invasive bladder cancer. J. Pathol. Clin. Res. 8, 143\u2013154 (2022).","journal-title":"J. Pathol. Clin. Res."},{"key":"55665_CR61","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.eururo.2016.02.028","volume":"70","author":"PA Humphrey","year":"2016","unstructured":"Humphrey, P. A., Moch, H., Cubilla, A. L., Ulbright, T. M. & Reuter, V. E. The 2016 WHO classification of tumours of the urinary system and male genital organs-part b: prostate and bladder tumours. Eur. Urol. 70, 106\u2013119 (2016).","journal-title":"Eur. Urol."},{"key":"55665_CR62","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1021\/acs.jproteome.2c00538","volume":"22","author":"RM Riley","year":"2023","unstructured":"Riley, R. M., Spencer Miko, S. E., Morin, R. D., Morin, G. B. & Negri, G. L. PeptideRanger: an R Package to optimize synthetic peptide selection for mass spectrometry applications. J. Proteome Res. 22, 526\u2013531 (2023).","journal-title":"J. Proteome Res."},{"key":"55665_CR63","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1021\/acs.jproteome.9b00328","volume":"19","author":"N Hulstaert","year":"2020","unstructured":"Hulstaert, N. et al. ThermoRawFileParser: modular, scalable, and cross-platform RAW file conversion. J. Proteome Res. 19, 537\u2013542 (2020).","journal-title":"J. Proteome Res."},{"key":"55665_CR64","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nmeth.4256","volume":"14","author":"AT Kong","year":"2017","unstructured":"Kong, A. T., Leprevost, F. V., Avtonomov, D. M., Mellacheruvu, D. & Nesvizhskii, A. I. MSFragger: ultrafast and comprehensive peptide identification in mass spectrometry-based proteomics. Nat. Methods 14, 513\u2013520 (2017).","journal-title":"Nat. Methods"},{"key":"55665_CR65","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1007\/s13361-016-1460-7","volume":"27","author":"M The","year":"2016","unstructured":"The, M., MacCoss, M. J., Noble, W. S. & Kall, L. Fast and accurate protein false discovery rates on large-scale proteomics data sets with percolator 3.0. J. Am. Soc. Mass Spectrom. 27, 1719\u20131727 (2016).","journal-title":"J. Am. Soc. Mass Spectrom."},{"key":"55665_CR66","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-15283-z","volume":"11","author":"SI Djomehri","year":"2020","unstructured":"Djomehri, S. I. et al. Quantitative proteomic landscape of metaplastic breast carcinoma pathological subtypes and their relationship to triple-negative tumors. Nat. Commun. 11, 1723 (2020).","journal-title":"Nat. Commun."},{"key":"55665_CR67","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1074\/mcp.TIR119.001646","volume":"19","author":"Y Zhu","year":"2020","unstructured":"Zhu, Y. et al. DEqMS: a method for accurate variance estimation in differential protein expression analysis. Mol. Cell Proteom. 19, 1047\u20131057 (2020).","journal-title":"Mol. Cell Proteom."},{"key":"55665_CR68","doi-asserted-by":"publisher","unstructured":"Korotkevich, G. et al. Fast gene set enrichment analysis. bioRxiv, 060012, https:\/\/doi.org\/10.1101\/060012 (2021).","DOI":"10.1101\/060012"},{"key":"55665_CR69","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon, A. et al. The molecular signatures database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417\u2013425 (2015).","journal-title":"Cell Syst."},{"key":"55665_CR70","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1023\/A:1023949509487","volume":"52","author":"S Monti","year":"2003","unstructured":"Monti, S., Tamayo, P., Mesirov, J. & Golub, T. Consensus clustering: a resampling-based method for class discovery and visualization of gene expression microarray data. Mach. Learn. 52, 91\u2013118 (2003).","journal-title":"Mach. Learn."},{"key":"55665_CR71","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1093\/bioinformatics\/btq170","volume":"26","author":"MD Wilkerson","year":"2010","unstructured":"Wilkerson, M. D. & Hayes, D. N. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics 26, 1572\u20131573 (2010).","journal-title":"Bioinformatics"},{"key":"55665_CR72","doi-asserted-by":"crossref","first-page":"W191","DOI":"10.1093\/nar\/gkz369","volume":"47","author":"U Raudvere","year":"2019","unstructured":"Raudvere, U. et al. g:Profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update). Nucleic Acids Res. 47, W191\u2013W198 (2019).","journal-title":"Nucleic Acids Res."},{"key":"55665_CR73","volume":"11","author":"Z Chen","year":"2020","unstructured":"Chen, Z. et al. Single-cell RNA sequencing highlights the role of inflammatory cancer-associated fibroblasts in bladder urothelial carcinoma. Nat. Commun. 11, 5077 (2020).","journal-title":"Nat. Commun."},{"key":"55665_CR74","doi-asserted-by":"crossref","first-page":"6395","DOI":"10.1038\/s41388-021-02055-2","volume":"40","author":"D Huang","year":"2021","unstructured":"Huang, D. et al. A highly annotated database of genes associated with platinum resistance in cancer. Oncogene 40, 6395\u20136405 (2021).","journal-title":"Oncogene"},{"key":"55665_CR75","first-page":"3","volume":"17","author":"M Martin","year":"2011","unstructured":"Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads. 2011 17, 3 (2011).","journal-title":"2011"},{"key":"55665_CR76","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"55665_CR77","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","volume":"25","author":"H Li","year":"2009","unstructured":"Li, H. et al. The sequence alignment\/map format and SAMtools. Bioinformatics 25, 2078\u20132079 (2009).","journal-title":"Bioinformatics"},{"key":"55665_CR78","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","volume":"30","author":"Y Liao","year":"2014","unstructured":"Liao, Y., Smyth, G. K. & Shi, W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30, 923\u2013930 (2014).","journal-title":"Bioinformatics"},{"key":"55665_CR79","unstructured":"Andrews, S. Babraham Bioinformatics (accessed 12 November 2021) https:\/\/www.bioinformatics.babraham.ac.uk\/projects\/fastqc\/"},{"key":"55665_CR80","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1093\/bioinformatics\/btv566","volume":"32","author":"K Okonechnikov","year":"2016","unstructured":"Okonechnikov, K., Conesa, A. & Garcia-Alcalde, F. Qualimap 2: advanced multi-sample quality control for high-throughput sequencing data. Bioinformatics 32, 292\u2013294 (2016).","journal-title":"Bioinformatics"},{"key":"55665_CR81","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1093\/bioinformatics\/btw354","volume":"32","author":"P Ewels","year":"2016","unstructured":"Ewels, P., Magnusson, M., Lundin, S. & Kaller, M. MultiQC: summarize analysis results for multiple tools and samples in a single report. Bioinformatics 32, 3047\u20133048 (2016).","journal-title":"Bioinformatics"},{"key":"55665_CR82","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"55665_CR83","doi-asserted-by":"crossref","first-page":"D543","DOI":"10.1093\/nar\/gkab1038","volume":"50","author":"Y Perez-Riverol","year":"2022","unstructured":"Perez-Riverol, Y. et al. The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences. Nucleic Acids Res. 50, D543\u2013D552 (2022).","journal-title":"Nucleic Acids Res."}],"updated-by":[{"DOI":"10.1038\/s41467-025-57187-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000}}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-55665-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-55665-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-55665-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T03:56:32Z","timestamp":1740196592000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-55665-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,1]]},"references-count":83,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["55665"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-55665-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4271858\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,1]]},"assertion":[{"value":"15 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41467-025-57187-w","URL":"https:\/\/doi.org\/10.1038\/s41467-025-57187-w","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.C.-S. has consulted for Sustained Therapeutics. D.M.B. serves on the Scientific Advisory Board and has equity in Acrivon Therapeutics. Peter Black has consulted for AbbVie, Astellas Pharma, AstraZeneca, EMD-Serono, Ferring, Pfizer, Janssen Oncology, Bayer, Merck, Sanofi Canada, Bristol-Myers Squibb, Prokarium, Combat, Nonagen, Nanobot, NanOlogy, Photocure, Sumitomo, TerSera, Tolmar, and Verity. He shares a patent with Veracyte which played no role or is linked to the work presented here (Inventors Elai Davicioni, Hussam Al-Deen Ashab, Nicholas Erho, Peter Black; EP 3 571 322 B8 date of publication and mention of the grant patent 07.06.2023). R.S. has consulted for Janssen Oncology. He shares a patent with Veracyte which played no role or is linked to the work presented here (Inventors Elai Davicioni, Hussam Al-Deen Ashab, Nicholas Erho, Peter Black; EP 3 571 322 B8 date of publication and mention of the grant patent 07.06.2023). The rest of authors had no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1240"}}